Psoriasis has long been understood through its visible skin plaques, but a growing body of research highlights that the disease is far more complex. Patients often show different disease trajectories, flare patterns, comorbidities, and responses to treatment, even when their skin symptoms look similar. This clinical heterogeneity, experts say, points to underlying biological differences that are not apparent from surface examination alone.
The scientific view of psoriasis has shifted from a keratinocyte-driven skin disorder to a systemic, immune-mediated inflammatory disease. The IL-23/IL-17 axis remains a cornerstone of pathogenesis models and therapy development, but it may not account for the full spectrum of real-world presentations. Increasingly, psoriasis is seen as the result of interactions among immune dysregulation, genetic susceptibility, environmental triggers, and crosstalk between innate and adaptive immunity.
One emerging focus is TYK2, an intracellular enzyme in the JAK-STAT pathway that transmits signals from several cytokine receptors, including those for IL-23, IL-12, and type I interferons. Because TYK2 sits at the intersection of multiple pathways implicated in psoriasis, it may help explain why patients with seemingly similar disease can have different clinical experiences and responses to therapy. As dermatologist Kenneth Gordon notes, studying these intersections could provide insight into the interconnected biology that drives psoriasis heterogeneity.